Moniz Michelle H, Kilbourne Amy M, Peahl Alex F, Waljee Jennifer F, Cocroft Shelytia, Simpson Carey, Kane Low Lisa, Bicket Mark C, Englesbe Michael J, Stout Molly J, Gunaseelan Vidhya, Bourdeau Althea, Hu May, Miller Carrie, Smith Shawna N
Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, United States.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States.
Front Glob Womens Health. 2025 Mar 14;6:1504511. doi: 10.3389/fgwh.2025.1504511. eCollection 2025.
Our objective is to determine the effect of a new national clinical practice guideline (CPG) for pain management after childbirth, as implemented with less vs. more intensive implementation support, on postpartum opioid prescribing.
A quasi-experimental analysis will measure the impact of post-childbirth pain management guidelines on opioid prescribing in a statewide hospital collaborative, overall and among key patient subgroups at risk for inequitable care and outcomes. We will also use a randomized, non-responder design and mixed-methods approaches to evaluate the effects of Replicating Effective Programs (REP), a theory-driven, scalable implementation intervention, and Enhanced REP (E-REP; i.e., REP augmented with facilitation, which is individualized consultation with site champions to overcome local barriers) on the uptake of the CPG. The study will include hospitals within the Obstetrics Initiative (OBI), a perinatal collaborative quality initiative funded by Blue Cross Blue Shield of Michigan that includes 68 member hospitals serving more than 120,000 postpartum people, over approximately 15 months. Hospitals not initially responding to REP-defined by performance <15th percentile of all OBI hospitals for (a) inpatient order for opioid-sparing postpartum pain management (e.g., scheduled acetaminophen and non-steroidal anti-inflammatory drugs when not contraindicated), or (b) amount of opioid prescribed at discharge-will be allocated via block randomization to continue REP or to E-REP. Using interrupted time series analyses, the primary analysis will evaluate the rate of postpartum opioid-sparing prescribing metrics at the time of discharge (primary outcome) and opioid prescription refills and high-risk prescribing (secondary outcomes) before and after CPG implementation with REP. We will evaluate inequities in outcomes by patient, procedure, prescriber, and hospital factors. Exploratory analyses will examine temporal trends in patient-reported outcomes and the effects of continued REP vs. E-REP among slower-responder sites. We will evaluate implementation outcomes (e.g., acceptability, feasibility, costs, needed REP and E-REP adaptations) using clinician and patient surveys and qualitative methods (ClinicalTrials.gov identifier: NCT06285123).
Findings will inform refinements to the REP and E-REP interventions and add to the literature on the effectiveness of facilitation to promote uptake of evidence-based clinical practices in maternity care.
我们的目标是确定一项新的全国产后疼痛管理临床实践指南(CPG)在实施时,较少与较多强化实施支持措施对产后阿片类药物处方的影响。
一项准实验分析将衡量产后疼痛管理指南对全州医院协作组中阿片类药物处方的影响,包括总体影响以及在面临不公平护理和结果风险的关键患者亚组中的影响。我们还将使用随机、无反应者设计和混合方法来评估复制有效项目(REP)的效果,REP是一种理论驱动、可扩展的实施干预措施,以及强化REP(E-REP,即通过促进增强的REP,也就是与机构负责人进行个性化咨询以克服当地障碍)对CPG采用情况的影响。该研究将纳入产科倡议(OBI)中的医院,OBI是一项由密歇根蓝十字蓝盾公司资助的围产期协作质量倡议,包括68家成员医院,为超过12万名产后患者服务,为期约15个月。最初对REP无反应的医院(根据以下标准定义:在所有OBI医院中,(a)阿片类药物节省型产后疼痛管理的住院医嘱(例如,在无禁忌证时定期使用对乙酰氨基酚和非甾体抗炎药)或(b)出院时开具的阿片类药物量处于第15百分位数以下)将通过整群随机化分配继续接受REP或E-REP。使用中断时间序列分析,主要分析将评估CPG在REP实施前后出院时的产后阿片类药物节省型处方指标(主要结局)以及阿片类药物处方续方和高风险处方(次要结局)。我们将按患者、手术、开处方者和医院因素评估结局的不公平性。探索性分析将研究患者报告结局的时间趋势以及反应较慢的机构中继续接受REP与E-REP的效果。我们将使用临床医生和患者调查以及定性方法评估实施结局(例如,可接受性、可行性、成本、所需的REP和E-REP调整)(ClinicalTrials.gov标识符:NCT06285123)。
研究结果将为完善REP和E-REP干预措施提供信息,并补充有关促进在产科护理中采用循证临床实践的促进措施有效性的文献。